Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Vasculitis
How do you approach tapering of tocilizumab used for a history of GCA with vision loss?
Related Questions
How long do you continue rituximab in patients with ANCA associated vasculitis who have achieved remission?
What treatment regimen would you recommend for a patient with biopsy-proven giant cell arteritis and diffuse cutaneous systemic sclerosis?
How do you determine which patients with ANCA associated vasculitis may be good candidates for reduced dose glucocorticoid tapering?
How would you approach a male in his 60s with bilateral optic perineuritis/neuritis on MRI, steroid-responsive bilateral jaw pain, normal ESR/CRP, negative temporal artery biopsy, and elevated IgG4?
How do you interpret a negative ANCA and a low positive PR3?
What options are available for patients who require high dose steroids while taking strong CYP4A4 inducers?
How soon after starting treatment for Takayasu arteritis do you decide on the need for any vascular interventions to manage chronic damage?
How would you manage a patient with Takayasu arteritis controlled on TNFi who develops erythema nodosum that is only partially responsive to NSAIDs?
Do you always pursue biopsy confirmation before diagnosing IgA vasculitis?
What would be your approach to managing severe ANCA-associated vasculitis in a patient who is also septic from a bacterial infection?
